qordata thought leaders and subject matter experts share their insights and experiences
While privacy laws in Europe show continuing evolution and attract views from both sides within the compliance/transparency space, another closely-related topic was under debate at the 7th Annual Global Transparency Reporting Congress in the UK. For transparency professionals, the decision to move towards pre-disclosure drew strong arguments from both sides. The Debate Not Ready For Pre-Disclosure As GDPR promises to award more privacy rights to physicians in Europe, does pre-disclosure make sense? One may argue against this, when considering the expenditure of time and funding this exercise demands. Even for drug and device companies ready to undertake the pre-disclosure exercise, accounting for the right technology, resources, and internal workflow are realistic, plausible obstacles. How would pre-disclosed data affect physician consent rates? […]
Accidental discovery. Life changing consequence. Happens all the time, doesn’t it? Penicillin wouldn’t have been discovered if Alexander Fleming hadn’t observed unusual growth in his lab equipment. For others in the life sciences industry—particularly in compliance—discoveries don’t always have happy endings. Data discoveries are best made quickly and internally. Yet, that doesn’t seem to happen often enough. In listing “Best Practices For Compliance Analytics,” at the 7th Annual Global Transparency Reporting Congress, Mohammad Ovais, CEO and founder qordata mentioned how this very basic step was overlooked by decision-makers across the pharma compliance/transparency space. For many pharmaceuticals, this happens because their compliance team defers to counterparts in technology. Should they wait for an analytics system to be up in place before […]
“If it ain’t broke, don’t fix it.” Pharmaceutical compliance serves the industry well by doing the exact opposite. In “Using Data Analysis For Business And Compliance Monitoring,” a qordata webinar I co-presented with Alice Cabrio, I described some of the proactive measures that have shifted compliance from functional support to an area of strategic centrality. Introducing Substantial Compliance at Roche Italy is one of them. Traditional Compliance, whose purpose is borne out of extrinsic reporting, is often reactive and diagnostic. Its approach is to meet expectations. Literally, to just comply. In other words, if the data in traditional compliance gives no indication of disease, there’s no need to look further. My team and I have managed to evolve things at […]
Mohammad Ovais, founder/CEO, qordata was one of the keynote speakers at the 7th Annual Global Transparency Reporting Congress in UK. Titled, “Best Practices For Compliance Analytics,” the session provided guidelines for optimizing internal data for Transparency/Compliance in the global pharmaceutical industry.